R1 Cloudmed Transaction Overview

Strong Financial Profile Expands Growth Opportunity Accretive on Multiple Financial Metrics Unlocks Meaningful Synergies Strong Cash Flow and Balance Sheet Flexibility R1.cloudmed. ▪ Unlocks TAM for modular offerings Meaningfully diversifies customer base ▪ Accelerates digitization, leveraging data and technology ■ 16% revenue CAGR from 2022 2026 ▪ 30%+ Adjusted EBITDA margin in 2026 Moderately accretive to R1's EPS and cash flow per share in first full year (2023) ■ Approximately $85M in run-rate cost synergies by the end of year 3, and $98M at full run rate ▪ Potential for significant revenue synergies ▪ Preserves flexibility to invest in the business 11

View entire presentation